Cargando…
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug resistance (MDR). Accumulation studies showed that te...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584989/ https://www.ncbi.nlm.nih.gov/pubmed/34769363 http://dx.doi.org/10.3390/ijms222111936 |
_version_ | 1784597581790183424 |
---|---|
author | Vagiannis, Dimitrios Budagaga, Youssif Morell, Anselm Zhang, Yu Novotná, Eva Skarka, Adam Kammerer, Sarah Küpper, Jan-Heiner Hanke, Ivo Rozkoš, Tomáš Hofman, Jakub |
author_facet | Vagiannis, Dimitrios Budagaga, Youssif Morell, Anselm Zhang, Yu Novotná, Eva Skarka, Adam Kammerer, Sarah Küpper, Jan-Heiner Hanke, Ivo Rozkoš, Tomáš Hofman, Jakub |
author_sort | Vagiannis, Dimitrios |
collection | PubMed |
description | Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug resistance (MDR). Accumulation studies showed that tepotinib potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, tepotinib inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. In subsequent drug combination experiments, tepotinib synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively. Remarkably, MDR-modulatory properties were confirmed in ex vivo explants derived from NSCLC patients. Furthermore, we demonstrated that anticancer effect of tepotinib is not influenced by the presence of ABC transporters associated with MDR, although monolayer transport assays designated it as ABCB1 substrate. Finally, tested drug was observed to have negligible effect on the expression of clinically relevant drug efflux transporters and CYP enzymes. In conclusion, our findings provide complex overview on the tepotinib’s drug interaction profile and suggest a promising novel therapeutic strategy for future clinical investigations. |
format | Online Article Text |
id | pubmed-8584989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85849892021-11-12 Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo Vagiannis, Dimitrios Budagaga, Youssif Morell, Anselm Zhang, Yu Novotná, Eva Skarka, Adam Kammerer, Sarah Küpper, Jan-Heiner Hanke, Ivo Rozkoš, Tomáš Hofman, Jakub Int J Mol Sci Article Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug resistance (MDR). Accumulation studies showed that tepotinib potently inhibits ABCB1 and ABCG2 efflux transporters, which was confirmed by molecular docking. In addition, tepotinib inhibited several recombinant cytochrome P450 (CYP) isoforms with varying potency. In subsequent drug combination experiments, tepotinib synergistically reversed daunorubicin and mitoxantrone resistance in cells with ABCB1 and ABCG2 overexpression, respectively. Remarkably, MDR-modulatory properties were confirmed in ex vivo explants derived from NSCLC patients. Furthermore, we demonstrated that anticancer effect of tepotinib is not influenced by the presence of ABC transporters associated with MDR, although monolayer transport assays designated it as ABCB1 substrate. Finally, tested drug was observed to have negligible effect on the expression of clinically relevant drug efflux transporters and CYP enzymes. In conclusion, our findings provide complex overview on the tepotinib’s drug interaction profile and suggest a promising novel therapeutic strategy for future clinical investigations. MDPI 2021-11-03 /pmc/articles/PMC8584989/ /pubmed/34769363 http://dx.doi.org/10.3390/ijms222111936 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vagiannis, Dimitrios Budagaga, Youssif Morell, Anselm Zhang, Yu Novotná, Eva Skarka, Adam Kammerer, Sarah Küpper, Jan-Heiner Hanke, Ivo Rozkoš, Tomáš Hofman, Jakub Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title | Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title_full | Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title_fullStr | Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title_full_unstemmed | Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title_short | Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo |
title_sort | tepotinib inhibits several drug efflux transporters and biotransformation enzymes: the role in drug-drug interactions and targeting cytostatic resistance in vitro and ex vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584989/ https://www.ncbi.nlm.nih.gov/pubmed/34769363 http://dx.doi.org/10.3390/ijms222111936 |
work_keys_str_mv | AT vagiannisdimitrios tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT budagagayoussif tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT morellanselm tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT zhangyu tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT novotnaeva tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT skarkaadam tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT kammerersarah tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT kupperjanheiner tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT hankeivo tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT rozkostomas tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo AT hofmanjakub tepotinibinhibitsseveraldrugeffluxtransportersandbiotransformationenzymestheroleindrugdruginteractionsandtargetingcytostaticresistanceinvitroandexvivo |